Vitiligo therapy: restoring immune privilege?
The therapeutic hypothesis proposed by Speeckaert and van Geel in this issue (1) is based on the dramatic effects of the new drugs targeting immune privilege checkpoints (PD1/PDL, CTLA4) in current advanced melanoma therapy as major inductors of vitiligo changes in the skin. Such striking clinical manifestations cannot be classified as mere side effects without considering possible consequences for spontaneously occurring vitiligo."
INSERM U 1035, BMGIC, University of Bordeaux, Bordeaux, France.
Katia
K
Boniface
INSERM U 1035, BMGIC, University of Bordeaux, Bordeaux, France.|National Reference Centre for Rare Skin Disorders, Department of Dermatology and Pediatric Dermatology, Bordeaux University Hospitals, Bordeaux, France.
Julien
J
Seneschal
INSERM U 1035, BMGIC, University of Bordeaux, Bordeaux, France.|National Reference Centre for Rare Skin Disorders, Department of Dermatology and Pediatric Dermatology, Bordeaux University Hospitals, Bordeaux, France.
Alain
A
Taïeb
INSERM U1053, Bordeaux Research in Translational Oncology, University of Bordeaux, Bordeaux, France.
Aksam
A
Merched
D060890:B7-H1 Antigen / Q000276:immunology; D060908:CTLA-4 Antigen / Q000276:immunology; D020022:Genetic Predisposition to Disease; D055106:Genome-Wide Association Study; D006801:Humans; D017496:Hypopigmentation; D000073860:Immune Privilege; D007107:Immune System; D007249:Inflammation; D008544:Melanocytes / Q000166:cytology; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology; D012306:Risk; D015398:Signal Transduction; D012867:Skin; D012878:Skin Neoplasms / Q000276:immunology / Q000628:therapy*; D014820:Vitiligo / Q000276:immunology* / Q000628:therapy*
D060890:B7-H1 Antigen; C423236:CD274 protein, human; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor
immune privilege; melanoma; vitiligo